TY - CHAP M1 - Book, Section TI - Chapter 457. Neuroblastoma A1 - Hogarty, Michael D. A1 - Brodeur, Garrett M. A2 - Rudolph, Colin D. A2 - Rudolph, Abraham M. A2 - Lister, George E. A2 - First, Lewis R. A2 - Gershon, Anne A. Y1 - 2011 N1 - T2 - Rudolph's Pediatrics, 22e AB - Neuroblastoma, a tumor of the sympathetic nervous system, is the most common solid tumor in childhood. Interestingly, some infants with metastatic disease experience complete tumor regression without therapy, and other patients may have maturation of their tumor into a benign ganglioneuroma. Nevertheless, the majority of patients have metastatic disease at diagnosis that progresses despite intensive multimodality therapy.1-3 Current risk classification schemes use biological and clinical features at diagnosis to predict tumor behavior and to stratify patients to an appropriate treatment. Children with tumors that have lower risk features are spared unnecessary therapies yet still achieve excellent outcomes. However, the survival of patients with high-risk neuroblastoma is still unacceptably low. Advances in understanding the molecular pathogenesis of this tumor, including how alterations in specific biological pathways impact tumor behavior, may lead to novel therapeutics to reduce toxicity in patients with favorable disease and improve outcomes in those with unfavorable disease.4,5 SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accesspediatrics.mhmedical.com/content.aspx?aid=7043537 ER -